Category - Developments

Developments

Reviva completes Phase 3 enrollment for brilaroxazine in schizophrenia

Reviva Pharmaceuticals (NASDAQ:RVPH) completed enrollment in the pivotal Phase 3 RECOVER study, evaluating brilaroxazine for schizophrenia, with 402 patients enrolled across 40 sites in the U.S., Europe, and Asia. “We...

August 17, 2023

Developments

Minghui enrolls first patient in Phase 3 trial for atopic dermatitis

Closely-held Minghui Pharmaceutical enrolled the first patient in the Phase 3 clinical study for MH004 cream targeting mild-to-moderate atopic dermatitis, a prevalent skin condition. The randomized, double-blind, and...

August 17, 2023

Developments

Keystone Dental Holdings to combine with Check-Cap

Closely-held Keystone Dental Holdings agreed to a definitive business combination with Check-Cap (NASDAQ:CHEK), with stockholders of Keystone becoming majority holders of the combined company. If completed, the business...

August 17, 2023

Developments

Eyenovia acquires U.S. rights for ocular asset from Formosa Pharmaceuticals

Eyenovia (NASDAQ:EYEN) entered an agreement with Taiwan-based Formosa Pharmaceuticals (TWO:6838) to acquire the exclusive U.S. rights to distribute and sell Formosa’s APP13007 (clobetasol propionate ophthalmic...

August 16, 2023

Developments

FDA clears Revance’s DAXXIFY injection for cervical dystonia

The FDA approved the first therapeutic indication for Revance Therapeutics’ (NASDAQ:RVNC) DAXXIFY for injection for the treatment of cervical dystonia in adults. Cervical dystonia is a chronic, debilitating disease in...

August 14, 2023

Developments

Anixa to present ovarian cancer CAR-T therapy at CAR-TCR Summit

Dr. Pamela Garzone, chief development officer of Anixa Biosciences (NASDAQ:ANIX) will present, “Developing a CAR-T for Ovarian Cancer and Other Solid Tumors,” at the 8th Annual CAR-TCR Summit in Boston...

August 14, 2023

Developments

Plus Therapeutics posts positive Phase 1 data in leptomeningeal metastases

Plus Therapeutics (NASDAQ:PSTV) reported positive data from the ReSPECT-LM clinical study evaluating the company’s lead radiotherapeutic, rhenium (Re-186) obisbemeda, for the treatment of leptomeningeal metastases (LM)...

August 11, 2023

Developments

IntelGenx first CDMO packaging accord to generate $9-million in revenue over 3 years

IntelGenx (TSX:IGX; OTCQB:IGXT) expects to generate $9-million in revenue over three years from an agreement for packaging a pharmaceutical oral film product that an undisclosed contract development and manufacturing...

August 11, 2023

Developments

Inversago Pharma accepts $1.1-billion offer from Novo Nordisk

Closely-held Inversago Pharma of Montreal agreed to be acquired by Denmark’s Novo Nordisk for up to $1.1-billion (U.S.) in cash if certain development and commercial milestones are achieved. Inversago Pharma is a...

August 10, 2023

Developments

Absci, Caltech receive Gates grant to develop affordable HIV vaccines

Absci (NASDAQ:ABSI) and leading researchers at the California Institute of Technology received a grant from the Bill & Melinda Gates Foundation for a joint effort to discover affordable HIV therapeutic vaccinations...

August 10, 2023

Category - Developments

Reviva completes Phase 3 enrollment for brilaroxazine in schizophrenia

Minghui enrolls first patient in Phase 3 trial for atopic dermatitis

Keystone Dental Holdings to combine with Check-Cap

Eyenovia acquires U.S. rights for ocular asset from Formosa Pharmaceuticals

FDA clears Revance’s DAXXIFY injection for cervical dystonia

Anixa to present ovarian cancer CAR-T therapy at CAR-TCR Summit

Plus Therapeutics posts positive Phase 1 data in leptomeningeal metastases

IntelGenx first CDMO packaging accord to generate $9-million in revenue over 3 years

Inversago Pharma accepts $1.1-billion offer from Novo Nordisk

Absci, Caltech receive Gates grant to develop affordable HIV vaccines

General

More